112 related articles for article (PubMed ID: 7902828)
1. Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy.
Jackson AM; Alexandrov AB; Gribben SC; Esuvarnathan K; James K
Int J Cancer; 1993 Dec; 55(6):921-5. PubMed ID: 7902828
[TBL] [Abstract][Full Text] [Related]
2. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.
Jackson AM; Alexandroff AB; Kelly RW; Skibinska A; Esuvaranathan K; Prescott S; Chisholm GD; James K
Clin Exp Immunol; 1995 Mar; 99(3):369-75. PubMed ID: 7882559
[TBL] [Abstract][Full Text] [Related]
3. Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.
Jackson AM; Alexandroff AB; McIntyre M; Esuvaranathan K; James K; Chisholm GD
J Clin Pathol; 1994 Apr; 47(4):309-12. PubMed ID: 7913098
[TBL] [Abstract][Full Text] [Related]
4. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.
Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA
J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992
[TBL] [Abstract][Full Text] [Related]
5. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy.
Jackson AM; Prescott S; Hawkyard SJ; James K; Chisholm G
Cancer Immunol Immunother; 1993; 36(1):25-30. PubMed ID: 8093683
[TBL] [Abstract][Full Text] [Related]
6. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumour necrosis factor-alpha.
Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD
J Urol; 1992 Nov; 148(5):1583-6. PubMed ID: 1433572
[TBL] [Abstract][Full Text] [Related]
7. Defective expression of adhesion molecules on human bladder tumour and human tumour cell lines.
Nouri AM; Hussain RF; Dos Santos AV; Oliver RT
Urol Int; 1996; 56(1):6-12. PubMed ID: 8903546
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy.
Esuvaranathan K; Alexandroff AB; McIntyre M; Jackson AM; Prescott S; Chisholm GD; James K
J Urol; 1995 Aug; 154(2 Pt 1):572-5. PubMed ID: 7609139
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
Jackson AM; Ivshina AV; Senko O; Kuznetsova A; Sundan A; O'Donnell MA; Clinton S; Alexandroff AB; Selby PJ; James K; Kuznetsov VA
J Urol; 1998 Mar; 159(3):1054-63. PubMed ID: 9474231
[TBL] [Abstract][Full Text] [Related]
10. Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.
Jackson AM; Alexandrov AB; Prescott S; James K
Cancer Immunol Immunother; 1995 Feb; 40(2):119-24. PubMed ID: 7882382
[TBL] [Abstract][Full Text] [Related]
11. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
[TBL] [Abstract][Full Text] [Related]
12. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
13. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
14. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
15. Purification and characterisation of soluble intercellular adhesion molecule-1 (sICAM-1) and its effect on cell-mediated cytolysis of tumour cells.
Young D; Jackson A; James K
Int J Oncol; 1997 Apr; 10(4):827-34. PubMed ID: 21533452
[TBL] [Abstract][Full Text] [Related]
16. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
[TBL] [Abstract][Full Text] [Related]
17. Autocrine regulation of ICAM-1 expression on bladder cancer cell lines: evidence for the role of IL-1 alpha.
Alexandroff AB; Jackson AM; Esuvaranathan K; Prescott S; James K
Immunol Lett; 1994 May; 40(2):117-24. PubMed ID: 7916330
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal keratinocytes are a source of soluble ICAM-1 molecules.
Budnik A; Trefzer U; Parlow F; Grewe M; Kapp A; Schöpf E; Krutmann J
Exp Dermatol; 1992 Jul; 1(1):27-30. PubMed ID: 1364253
[TBL] [Abstract][Full Text] [Related]
19. Detection and quantification of soluble intercellular adhesion molecule-1 (sICAM-1) in the serum and urine of patients with bladder cancer.
Shi BB; Goya N; Okuda H; Ryoji O; Nakazawa H; Toma H
Int J Urol; 1998 Jul; 5(4):324-8. PubMed ID: 9712439
[TBL] [Abstract][Full Text] [Related]
20. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1.
Jackson AM; Alexandrov AB; Prescott S; James K; Chisholm GD
Immunology; 1992 Jun; 76(2):286-91. PubMed ID: 1353063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
